Skip to main
PAVM
PAVM logo

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. is recognized for its significant upside potential, as the current valuation reflects a balance between the company's inherent risks and its substantial growth opportunities. The company's diverse lines of business—Diagnostics, Medical Devices, and Digital Health—position it well for expansion, particularly with products like EsoGuard and the Veris Cancer Care Platform expected to gain traction in the 2025/26 timeframe. Additionally, the recent adjustments to price targets based on a net present value analysis indicate a favorable outlook for investors considering the company's early-stage commercialization efforts.

Bears say

PAVmed Inc reported a pro forma net loss of $0.8 million, translating to an earnings per share (EPS) of $(0.05), which was notably better than the consensus estimate range of $(0.13) to $(0.25). However, the company's declining performance in its flagship EsoGuard testing, with a decrease to 2,756 tests processed in Q2 from 3,034 in Q1 and 4,042 in Q4 of the previous year, raises concerns about its commercial viability and market demand. Additionally, significant risks surrounding liquidity, regulatory approvals, and competitive pressures further exacerbate the negative outlook for PAVmed's financial health and future growth potential.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.